Dr Lei Wang and colleagues from China assessed the efficacy and safety of direct-acting antivirals (DAA)-based antiviral therapies for HCV patients with stage 4-5 chronic kidney disease.
The researchers conducted a systematic literature search in PubMed, EMBASE, Web of Science, and CENTRAL on the Cochrane Library without time and language limitations.
The search strategy used was “(End stage renal disease OR chronic kidney failure OR severe renal impairment OR chronic kidney disease OR dialysis) AND (sofosbuvir OR simeprevir OR grazoprevir OR elbasvir OR ombitasvir OR paritaprevir OR ritonavir OR dasabuvir OR daclatasvir OR asuparevir OR direct-acting antiviral OR DAA)”.
|The pooled incidence of serious adverse events was 12%|
Sustained virologic response at 12 weeks after the end of treatment, adverse events, and/or serious adverse events with 95% confidence intervals were pooled.
The research team identified 11 studies, comprizing a total of 264 patients for the meta-analysis.
The team found that pooled sustained virologic response at 12 weeks after the end of treatment rates were 93%, 89% and 95% in total population, patients with sofosbuvir-based therapies and patients with non-sofosbuvir-based therapies respectively.
For HCV genotype 1 patients, the researchers observed that the pooled sustained virologic response at 12 weeks after the end of treatment rate was 93%.
The pooled incidence of serious adverse events was 12%.
The researchers noted that pooled discontinuation rate because of adverse events or SAEs in our meta-analysis was 2%.
Dr Wang's team comments, "DAA-based antiviral therapies are effective and well-tolerated for HCV patients with stage 4-5 chronic kidney disease."